**Massachusetts HIV Epidemiologic Profile**

**Statewide Report – Data as of 7/1/2024**, **Accessible MS Word Version, optimized for screen reader use**

*Please note that while the content of this report is the same as the pdf version, the format and pagination have been modified significantly to optimize use with screen readers to ensure access for audiences who are blind or visually impaired.*

**Suggested citation:**

Massachusetts Department of Public Health, Bureau of Infectious Disease and Laboratory Sciences. Massachusetts HIV Epidemiologic Profile, Statewide Report – Data as of 7/1/2024 <https://www.mass.gov/lists/hivaids-epidemiologic-profiles>Published September 2024. Accessed [date].

**Bureau of Infectious Disease and Laboratory Sciences**  
**Massachusetts Department of Public Health**

**Jamaica Plain Campus/State Public Health Laboratory**

305 South Street  
Jamaica Plain, MA 02130

**Questions about this report**

Tel: (617) 983-6560

**To reach the Reporting and Partner Services Line[[1]](#footnote-2)**

Tel: (617) 983-6999

**To speak to the on-call epidemiologist**

Tel: (617) 983-6800

**Questions about infectious disease reporting**

Tel: (617) 983-6801

**Requests for additional data**

<https://www.mass.gov/lists/infectious-disease-data-reports-and-requests>

**HIV Data Dashboard**

https://www.mass.gov/info-details/hiv-data-dashboard

**Slide sets for HIV Epidemiologic Profile Reports**

<https://www.mass.gov/lists/hivaids-epidemiologic-profiles>

Contents

[**LIST OF COMMONLY USED ACRONYMS** 3](#_Toc168575088)

[**EXECUTIVE SUMMARY** 4](#_Toc168575089)

[**EPIDEMIC AT A GLANCE** 9](#_Toc168575090)

[**TRENDS IN HIV INFECTION DIAGNOSES OVER TIME** 11](#_Toc168575091)

[**RECENT HIV INFECTION DIAGNOSES** 16](#_Toc168575092)

[**PERSONS LIVING WITH HIV INFECTION** 22](#_Toc168575093)

[**MORTALITY** **AMONG INDIVIDUALS WITH HIV** 27](#_Toc168575094)

[**GEOGRAPHIC DISTRIBUTION OF HIV INFECTION** 35](#_Toc168575095)

[**HIV CARE CONTINUUM** 40](#_Toc168575096)

[**SOCIAL VULNERABILITY INDEX** 45](#_Toc168575097)

[**TECHNICAL NOTES** 46](#_Toc168575098)

# LIST OF COMMONLY USED ACRONYMS

|  |  |
| --- | --- |
| **AFAB** | Assigned Female at Birth |
| **AI/AN** | American Indian/Alaska Native |
| **AIDS** | Acquired Immunodeficiency Syndrome |
| **AMAB** | Assigned Male at Birth |
| **API** | Asian/Pacific Islander |
| **BIDLS** | Bureau of Infectious Disease and Laboratory Sciences |
| **DPH** | (Massachusetts) Department of Public Health |
| **HIV** | Human Immunodeficiency Virus |
| **HSR** | Health Service Region |
| **HTSX** | Heterosexual Sex |
| **IDU** | Injection Drug Use |
| **MSM** | Male-to-Male Sex, Men Who Have Sex with Men |
| **N** | Number |
| **N/A** | Not Applicable |
| **NH** | Non-Hispanic |
| **NIR** | No Identified Risk |
| **PLWH** | Persons (or Individuals) Living with HIV Infection |
| **Pres. HTSX** | Presumed Heterosexual Sex |
| **PR/USD** | Puerto Rico/United States Dependency |
| **PWID** | Persons Who Inject Drugs |

# EXECUTIVE SUMMARY

**Impact of COVID-19 on HIV Surveillance Data**

The coronavirus disease 2019 (COVID-19) pandemic had a large impact on the screening, treatment, and surveillance of other infectious diseases from 2020 to 2023. Nationally, the Centers for Disease Control and Prevention (CDC) observed significant declines in HIV testing (and diagnoses) during the COVID-19 pandemic that are likely attributed to interruptions in the availability of clinical services, patient hesitancy in accessing face-to-face clinical services, and shortages in HIV testing reagents/materials.[[2]](#footnote-3) At time of publication, the full effect of the COVID-19 pandemic on case detection and reporting and efforts to control the spread of infectious disease in the Commonwealth has yet to be determined. As such, please interpret 2020 to 2023 HIV surveillance data presented in this report with caution.

**Epidemic at a Glance**

* The number of persons living with HIV infection (PLWH) in Massachusetts increased by 11% from 21,785 in 2014 to 24,119 in 2023. [[3]](#footnote-4)
* After averaging approximately 640 diagnoses per year from 2014 to 2018 (five-year average = 636), the number of new HIV infection diagnoses declined to 532 in 2019. In 2020, the number of new HIV infection diagnoses further declined to 434 and then remained at this lower level in 2021 and 2022, when there were 449 and 446 diagnoses, respectively. However, caution should be used in the interpretation of this decline and subsequent stabilization due to the impact of COVID-19 on access to HIV testing and care services, and case surveillance activities. In 2023, the number of new HIV infection diagnoses (N=540) returned to pre-pandemic levels, increasing by 21% compared to the prior year. The largest increases in HIV diagnoses from 2022 to 2023 were amongindividuals with male-to-male sex (MSM) exposure mode (by 35% from 168 to 227), Black non-Hispanic individuals (by 32% from 151 to 200), 40 – 49 year olds (by 35% from 74 to 100), and individuals diagnosed in the Central HSR (by 94% from 33 to 64).
* The number of deaths due to any cause among individuals reported with HIV infection increased by 32% from 279 in 2014 to a peak of 367 in 2022, and then decreased by 16% to 307 in 2023.
* Although there have been reductions in cases over the past ten years, vulnerable and historically marginalized populations remain disproportionately impacted:
  + Men who have sex with men (MSM) continued to represent the largest proportion of new HIV infection diagnoses (39% overall and 54% among individuals assigned male at birth [AMAB] in 2021–2023).
  + Individuals with IDU exposure mode accounted for 32% of deaths among individuals with HIV in 2023 but only 14% of all PLWH.

**Trends in HIV Infection Diagnoses Over Time**

* The number of individuals diagnosed with HIV infection has decreased over the past decade in Massachusetts, but disparities persist by sex at birth, exposure mode, race/ethnicity, place of birth, and age.
* Male-to-male sex (MSM) remained the predominant exposure mode from 2014 to 2023.[[4]](#footnote-5)
* The number of reported cases with injection drug use (IDU) as the primary exposure mode increased from a low of 31 in 2014 to a peak of 116 in 2017, and then decreased to 59 in 2019. The increase in 2017 was primarily due to an outbreak among persons who inject drugs (PWID) in the northeast part of the state between 2016 and 2018.[[5]](#footnote-6) Following a focused public health response, the number of HIV infection diagnoses attributed to IDU in the northeast has decreased. However, in early 2019, a new cluster of HIV infection was identified in Boston among PWID who were experiencing or had experienced recent homelessness, and the total statewide number of reported cases with IDU as the primary exposure increased to 82 in 2021. Following another focused public health response, the number of HIV infection diagnoses attributed to IDU decreased by 54% to 38 cases in 2023.
* As of July 1, 2024, a total of 213 cases diagnosed since November 2018 have been investigated and identified as part of the Boston cluster. As it is an active cluster of concern, additional cases will continue to be investigated and added. Emerging trends among those newly diagnosed in the Boston cluster (N=15 cases diagnosed in 2023) include an increase in polysubstance and methamphetamine use.[[6]](#footnote-7)
* The distributions of individuals diagnosed with HIV infection by sex assigned at birth and exposure mode remained relatively stable, while distributions by race/ethnicity, age at diagnosis, and place of birth shifted from 2014 to 2023:
  + The proportion of HIV infection diagnoses among White (non-Hispanic) individuals decreased from 35% to 27%, while it increased from 27% to 32% among Hispanic/Latinx individuals and from 33% to 37% among Black (non-Hispanic) individuals.
  + The proportion of HIV infection diagnoses among 30–39 year-olds increased from 24% to 35%, while it decreased from 24% to 19% among 40–49 year-olds.
  + The proportion of HIV infection diagnoses among individuals born in the US decreased from 58% to 51%, while it increased from 37% to 47% among individuals born outside the US.

**Recent HIV Infection Diagnoses**

* Those with no identified risk (NIR) comprised the second largest exposure mode group reported to the Massachusetts Department of Public Health (DPH), accounting for 28% of recent HIV infection diagnoses and consisting predominantly of individuals AMAB (73%), individuals born outside the US (58%), and Black (non-Hispanic) individuals (50%). Beginning in 2019, all new diagnoses of HIV infection were assigned to field epidemiologists for partner services, education, and linkage to HIV care. Please note that although field epidemiologists offer additional support in the collection of risk information as part of this process, some of the information doesn’t meet the CDC-defined exposure mode categories. For example, risks occurring outside the US, such as transfusion/transplant risk (blood product), are not assigned as a primary exposure mode because it is not possible to verify the information internationally, so these cases would be assigned no identified risk. DPH will collect and maintain expanded risk information for local analyses and future use in case the CDC-defined exposure mode categories are updated.
* One in eight (13%) individuals AFAB and diagnosed with HIV infection from 2021 to 2023[[7]](#footnote-8) reported IDU as their primary exposure mode, compared to one in nine (11%) individuals AMAB.
* Black (non-Hispanic) and Hispanic/Latinx individuals were diagnosed with HIV infection during 2021–2023 at rates 11 and five times that of White (non-Hispanic) individuals, respectively.
* During 2021 to 2023, 45% (N=645) of all individuals diagnosed with HIV infection were born outside the US. This proportion varied by race/ethnicity: 74% of Asian/Pacific Islander individuals diagnosed with HIV infection were born outside the US, compared to 67% of Black (non-Hispanic), 53% of Hispanic/Latinx, and 9% of White (non-Hispanic) individuals. An additional 7% of Hispanic/Latinx individuals diagnosed with HIV infection during this time period were born in Puerto Rico/US Dependencies.

**Persons Living with HIV Infection (PLWH)**

* Challenges to achieving health equity in the prevention and care of HIV infection remain:
  + Racial/ethnic disparities persist among PLWH, and marked differences exist by exposure mode, current gender, place of birth, and geographic region of residence in the state.
  + MSM was the most frequently reported exposure mode, accounting for 40% of PLWH overall and 56% of individuals AMAB living with HIV infection.
  + While 12% of all Massachusetts residents live in the Boston HSR, it is the current residence of 26% of PLWH.

**Mortality Among Individuals Reported with HIV**

* Disparities in mortality among individuals reported with HIV paralleled those in diagnosis rates by sex assigned at birth and race/ethnicity but not exposure mode. Individuals with IDU exposure mode were over-represented among HIV-positive individuals who died. The leading causes of death among individuals reported with HIV infection with IDU and IDU/MSM exposure mode who died in 2022[[8]](#footnote-9) (with a known cause) were external causes of injuries[[9]](#footnote-10) and poisonings (which includes opioid overdoses) which accounted for 36% (N=53/147) of deaths, HIV which accounted for 16% (N=23/147) of deaths, cancer which accounted for 11% (N=16/147) of deaths, and heart disease which accounted for 8% (N=12/147) (*final* *cause of death is not yet available for all 2023 deaths among individuals with HIV as of 7/1/2024*).
* The average age at death among individuals reported with HIV increased by 6.3 years, from 53.8 years in 2014 to 60.1 years in 2023. For comparison, the average age at death of the general Massachusetts population remained between 75.1 and 76.8 from 2014 to 2023.[[10]](#footnote-11)
* Survival of individuals diagnosed with AIDS has increased over time. In the earliest cohort of AIDS diagnoses (1989–1993), estimated survival at five years after AIDS diagnosis was 26%, compared to 88% in the most recent cohort (2019–2023).
* The proportion of deaths among individuals reported with HIV infection attributed to HIV-related causes decreased from 28% (N=43/155) in 2014 to 16% (N=57/355) in 2022. The leading non HIV-related causes of death among individuals reported with HIV infection who died in 2022 (with a known cause) were external causes of injuries and poisonings (which includes opioid overdoses) which accounted for 26% (N=91/355) of deaths, cancer which accounted for 16% (N=57/355) of deaths, and heart disease which accounted for 11% (N=40/355) of deaths (*final cause of death is not yet available for all 2023 deaths as of 7/1/2024*).

**Geographic Distribution of HIV Infection**

* The cities and towns with the highest average annual rate of HIV infection diagnosis during 2021 to 2023 included Brockton (23.7 per 100,000), Boston (17.3), Chelsea (17.2), Malden (14.6), and Lynn (14.5).[[11]](#footnote-12) Boston had the highest number of new HIV infection diagnoses from 2021–2023 (N=351), followed by Brockton (N=75), and Worcester (N=70).
* Suffolk County was selected as one of 48 counties nationally that was prioritized for funding in the U.S. Health and Human Services initiative “Ending the HIV Epidemic (EHE): A Plan for America”. Suffolk County had the highest average age-adjusted rate of HIV infection diagnosis during 2021 to 2023 among all Massachusetts counties at 14.7 per 100,000.

**The Massachusetts HIV Care Continuum**

* Among 419 individuals newly diagnosed with HIV infection in 2022 (and alive in Massachusetts through 2023), [[12]](#footnote-13) 83% overall achieved viral suppression,[[13]](#footnote-14) increasing to 90% among those linked to care,[[14]](#footnote-15) and to 93% among those retained in care[[15]](#footnote-16). Viral suppression was lowest among individuals with IDU and MSM/IDU exposure modes (54% and 73%, respectively, compared to 85% to 96% among other exposure modes).
* Among 22,837 persons living with HIV infection at the end of 2023 (and diagnosed through 2022), 64% were virally suppressed,[[16]](#footnote-17) 4% were not virally suppressed, and 32% did not have a viral load test done in 2023. Viral suppression increased to 91% among those engaged in care [[17]](#footnote-18) and to 95% among those retained in care[[18]](#footnote-19). Please note that the rate of viral suppression may be underestimated as the total number of PLWH used to calculate these rates includes all individuals who have ever been diagnosed with HIV infection in Massachusetts, with no evidence of death or having moved out of the state or country. See the section, [**Massachusetts HIV Care Continuum**](#_HIV_CARE_CONTINUUM) – PLWH for more information.

# EPIDEMIC AT A GLANCE

The number of persons living with HIV infection (PLWH) in Massachusetts increased by 11% from 21,785 in 2014 to 24,119 in 2023. [[19]](#footnote-20) After averaging approximately 640 diagnoses per year from 2014 to 2018 (five-year average = 636), the number of new HIV infection diagnoses declined to 532 in 2019. In 2020, the number of new HIV infection diagnoses further declined to 434 and then remained at this lower level in 2021 and 2022, when there were 449 and 446 diagnoses, respectively. However, caution should be used in the interpretation of this decline and subsequent stabilization due to the impact of COVID-19 on access to HIV testing and care services, and case surveillance activities. In 2023, the number of new HIV infection diagnoses (N=540) returned to pre-pandemic levels, increasing by 21% compared to the prior year. The number of deaths due to any cause among individuals reported with HIV infection increased by 32% from 279 in 2014 to a peak of 367 in 2022, and then decreased by 16% to 307 in 2023.

**FIGURE 1:** History of the HIV epidemic, Massachusetts 2014–2023

The figure displays trends in the annual number of new HIV diagnoses and deaths among individuals with HIV/AIDS from 2014-2023.


The figure displays a trend in the annual number of persons living with HIV infection from 2014-2023.


**EPIDEMIC AT A GLANCE**

N =540 New HIV diagnoses in MA in 2023[[20]](#footnote-21)

N = 24,119 Persons living with HIV infection in MA as of 12/31/2023

N = 307 Deaths among individuals reported with HIV in MA in 2023

Men who have sex with men (MSM) continued to represent the largest proportion of new HIV infection diagnoses: 39% of all new HIV infection diagnoses in 2021–2023, and 54% among individuals assigned male at birth (AMAB).

During 2021–2023, the HIV infection diagnosis rates among Black (non-Hispanic) and Hispanic/Latinx individuals were 11 and five times that of White (non-Hispanic) individuals, respectively.

Individuals with injection drug use (IDU) exposure mode accounted for 32% of deaths among individuals reported with HIV in 2023 but only 14% of all PLWH.

# TRENDS IN HIV INFECTION DIAGNOSES OVER TIME

**FIGURE 2:** Trends in HIV infection diagnoses, Massachusetts 2014 – 2023[[21]](#footnote-22)

|  |  |  |
| --- | --- | --- |
| **HIV Infection Diagnoses** | **2014** | **2023** |
| **Total** | 651 | 540 |
| **Sex Assigned at Birth** |  |  |
| Assigned Male Sex | 486 | 397 |
| Assigned Female Sex | 165 | 143 |
| **Race/Ethnicity** |  |  |
| White NH | 225 | 145 |
| Black NH | 212 | 200 |
| Hispanic/Latinx | 177 | 171 |
| API | 30 | 14 |
| Other/Unknown | 7 | 10 |
| **Age Group (Years)** |  |  |
| 0-12 | 3 | 3 |
| 13-19 | 16 | 12 |
| 20-29 | 181 | 133 |
| 30-39 | 158 | 187 |
| 40-49 | 154 | 100 |
| 50-59 | 94 | 68 |
| 60-69 | 35 | 31 |
| 70+ | 10 | 6 |
| **Exposure Mode** |  |  |
| MSM | 320 | 227 |
| IDU | 31 | 38 |
| MSM/IDU | 17 | 14 |
| HTSX | 38 | 25 |
| Other[[22]](#footnote-23) | 4 | 3 |
| Pres. HTSX | 86 | 82 |
| NIR | 155 | 151 |
| **Place of Birth** |  |  |
| US | 375 | 276 |
| PR/USD[[23]](#footnote-24) | 35 | 8 |
| Non-US | 241 | 256 |
| **Health Service Region** |  |  |
| Boston | 204 | 142 |
| Central | 45 | 64 |
| Metro West | 108 | 62 |
| Northeast | 119 | 97 |
| Southeast | 96 | 111 |
| Western | 66 | 57 |
| Prisoner | 12 | 6 |

**Overall**

The number of new HIV infection diagnoses decreased by 31% from 2014 to 2022 and then increased by 21% in 2023.[[24]](#footnote-25) Distributions by sex assigned at birth and exposure mode remained relatively stable, while distributions by race/ethnicity, age at diagnosis, and place of birth shifted.

**By Sex Assigned at Birth**

HIV infection diagnoses show a slightly larger decrease among individuals AMAB (by 18%, from 486 to 397) than AFAB (by 13%, from 165 to 143).

**By Race/Ethnicity**

HIV infection diagnoses decreased among Asian/Pacific Islander individuals (by 53%, from 30 to 14) and White (non-Hispanic) individuals (by 36%, from 225 to 145), but remained relatively stable among Hispanic/Latinx individuals (from 177 to 171), and Black (non-Hispanic) individuals (from 212 to 200). The proportion of HIV infection diagnoses among White (non-Hispanic) individuals decreased from 35% to 27%, while it increased from 27% to 32% among Hispanic/Latinx individuals, and from 33% to 37% among Black (non-Hispanic) individuals.

**By Age at HIV Infection Diagnosis**

HIV infection diagnoses remained stable among 0–12 year-olds (at three), decreased among 13–19 year-olds (by 25%, from 16 to 12), 20–29 year-olds (by 27%, from 181 to 133), 40–49 year-olds (by 35%, from 154 to 100), 50–59 year-olds (by 28%, from 94 to 68), 60–69 year-olds (by 11%, from 35 to 31), and 70+ year-olds (from 10 to six), but increased among 30–39 year-olds (by 18%, from 158 to 187). The proportion of HIV infection diagnoses among 30–39 year-olds increased from 24% to 35%, while it decreased from 24% to 19% among 40–49 year-olds.

**By Exposure Mode**

HIV infection diagnoses decreased among individuals with heterosexual sex (by 34%, from 38 to 25) and male-to-male sex (MSM) (by 29%, from 320 to 227) exposure modes and remained relatively stable among individuals with presumed heterosexual sex (from 86 to 82), no identified risk (from 155 to 151), and “other” exposure modes (from four to three). All diagnoses in the other category were related to pediatric exposures,[[25]](#footnote-26) with no confirmed clotting factor, transfusion, or transplant-related exposures in the ten-year time period. The number of reported cases with injection drug use (IDU) as the primary exposure mode increased by 39% from 59 in 2019 to 82 in 2021. This was primarily due to a cluster of HIV infection identified in early 2019 in Boston among PWID who were experiencing or had experienced recent homelessness. Following a focused public health response, the number of HIV infection diagnoses attributed to IDU decreased by 54% to 38 in 2023.[[26]](#footnote-27)

**By Place of Birth**

HIV infection diagnoses decreased among individuals born in PR/USD (by 77%, from 35 to 8) and individuals born in the US (by 26%, from 375 to 276), and increased slightly among individuals born outside the US (by 6% from 241 to 256). The proportion of HIV infection diagnoses among individuals born in the US decreased from 58% to 51%, while it increased from 37% to 47% among individuals born outside the US.

**FIGURE 3:** Trends in HIV infection diagnoses by sex assigned at birth, Massachusetts 2014 – 2023[[27]](#footnote-28)

**Assigned Male Sex at Birth:**

|  |  |  |
| --- | --- | --- |
| **HIV Infection Diagnoses** | **2014** | **2023** |
| **Total** | 486 | 397 |
| **Race/Ethnicity** |  |  |
| White NH | 189 | 116 |
| Black NH | 122 | 114 |
| Hispanic/Latinx | 142 | 146 |
| API | 26 | 14 |
| Other/Unknown | 7 | 7 |
| **Age Group (Years)** |  |  |
| 0-12 | 2 | 1 |
| 13-19 | 11 | 11 |
| 20-29 | 149 | 116 |
| 30-39 | 113 | 133 |
| 40-49 | 115 | 67 |
| 50-59 | 64 | 48 |
| 60-69 | 23 | 19 |
| 70+ | 9 | 2 |
| **Exposure Mode** |  |  |
| MSM | 320 | 227 |
| IDU | 19 | 25 |
| MSM/IDU | 17 | 14 |
| HTSX | 12 | 11 |
| Other[[28]](#footnote-29) | 3 | 1 |
| NIR | 115 | 119 |
| **Place of Birth** |  |  |
| US | 306 | 233 |
| PR/USD[[29]](#footnote-30) | 24 | 7 |
| Non-US | 156 | 157 |

**Assigned Female Sex at Birth:**

|  |  |  |
| --- | --- | --- |
| **HIV Infection Diagnoses** | **2014** | **2023** |
| **Total** | 165 | 143 |
| **Race/Ethnicity** |  |  |
| White NH | 36 | 29 |
| Black NH | 90 | 86 |
| Hispanic/Latinx | 35 | 25 |
| API | 4 | 0 |
| Other/Unknown | 0 | 3 |
| **Age Group (Years)** |  |  |
| 0-12 | 1 | 2 |
| 13-19 | 5 | 1 |
| 20-29 | 32 | 17 |
| 30-39 | 45 | 54 |
| 40-49 | 39 | 33 |
| 50-59 | 30 | 20 |
| 60-69 | 12 | 12 |
| 70+ | 1 | 4 |
| **Exposure Mode** |  |  |
| IDU | 12 | 13 |
| HTSX | 26 | 14 |
| Other | 1 | 2 |
| Pres. HTSX | 86 | 82 |
| NIR | 40 | 32 |
| **Place of Birth** |  |  |
| US | 69 | 43 |
| PR/USD | 11 | 1 |
| Non-US | 85 | 99 |

**Race/Ethnicity by Sex Assigned at Birth**

From 2014 to 2023,[[30]](#footnote-31) the number of HIV infection diagnoses decreased 46% among Asian/Pacific Islander individuals assigned male at birth (AMAB), 39% among White (non-Hispanic) individuals AMAB, and 7% among Black (non-Hispanic) individuals AMAB, while it remained stable among Hispanic/Latinx individuals AMAB. Among individuals assigned female at birth (AFAB), the number of diagnoses decreased 29% among Hispanic/Latinx individuals AFAB, 19% among White (non-Hispanic) individuals AFAB, and remained relatively stable among Black (non-Hispanic) individuals AFAB.

**Exposure Mode by Sex Assigned at Birth**

The number of HIV infection diagnoses decreased among individuals AMAB with MSM and MSM/IDU exposure modes, increased slightly among those with IDU exposure mode, and remained relatively stable among those with HTSX and NIR exposure modes. The number of diagnoses decreased among individuals AFAB with heterosexual sex and NIR exposure modes and remained relatively stable among those with IDU and presumed heterosexual exposure modes.

**Place of Birth by Sex Assigned at Birth**

From 2014 to 2023, the number of HIV infection diagnoses among individuals born in the US and Puerto Rico/US Dependencies decreased for individuals AMAB and AFAB, while the number born outside the US remained stable among individuals AMAB and increased among individuals AFAB.

# RECENT HIV INFECTION DIAGNOSES

*Who is most at risk for HIV infection? Recent HIV infection diagnoses are the best available indicator for who is most at risk for HIV infection. Monitoring new diagnoses helps us to determine who is affected and inform effective prevention activities.*

**FIGURE 4.** Percentage of individuals diagnosed with HIV infection by current gender, age, race/ethnicity, and exposure mode, Massachusetts 2021 – 2023 (N=1,435)

**The figure is a series of bar charts displaying the distribution of recent HIV diagnoses by current gender, age, race/ethnicity, and exposure mode.
**

The number of individuals diagnosed with HIV infection has decreased over the past decade in Massachusetts, but disparities persist by current gender, exposure mode, and race/ethnicity. Individuals newly diagnosed with HIV infection in Massachusetts during 2021–2023[[31]](#footnote-32) were predominantly male (71%), young (24% 20–29 year-olds and 35% 30–39 year-olds), Black (non-Hispanic) (35%), with an exposure mode of MSM (39%). While MSM was the leading exposure mode, a large percentage of new HIV infection diagnoses had no identified risk (28%).

**FIGURE 5.** Percentage of individuals diagnosed with HIV infection by race/ethnicity and place of birth, Massachusetts 2021 – 2023

The figure is a stacked bar chart displaying the distribution of recent HIV diagnoses by place of birth (non-US, Puerto Rico/US Dependency, or US) for each of four racial/ethnic groups: White NH (N=437), Black NH (N=503), Hispanic/Latinx (N=434), and Asian/Pacific Islander (N=42).


Figure 5 Notes: ii US born and Puerto Rico/USD categories are combined for Black non-Hispanic individuals due to small numbers to adhere to cell suppression rules

iii 94% of individuals diagnosed with HIV infection from 2021–2023 who were born in a US dependency (USD) were born in Puerto Rico (PR)

Seventy-four percent of Asian/Pacific Islander individuals diagnosed with HIV infection during 2021–2023[[32]](#footnote-33) were born outside the US, compared to 67% of Black (non-Hispanic), 53% of Hispanic/Latinx, and 9% of White (non-Hispanic) individuals.

**FIGURE 6.** Percentage of individuals diagnosed with HIV infection by race/ethnicity, age, exposure mode, and place of birth by sex assigned at birth, Massachusetts 2021 – 2023[[33]](#footnote-34)

(**AMAB, N=1,039; AFAB, N=396**)

The figure is a series of bar charts displaying a comparison of the distribution of recent HIV diagnoses for individuals assigned male at birth (AMAB) and individuals assigned female at birth (AFAB) by race/ethnicity, age, exposure mode, and place of birth.


The distributions of new HIV infection diagnoses by race/ethnicity, age, exposure mode, and place of birth varied by sex assigned at birth: the largest proportions of individuals assigned male at birth (AMAB) were White (non-Hispanic) and Hispanic/Latinx (both 34%), while the largest proportion of individuals assigned female at birth (AFAB) was Black (non-Hispanic) (57%). A larger proportion of individuals AMAB (28%) than AFAB (13%) was diagnosed between the ages of 20 and 29 years. MSM was the predominant exposure mode among individuals AMAB (54%), while presumed heterosexual sex was the predominant exposure mode among individuals AFAB (47%). A larger proportion of individuals AFAB (61%) than AMAB (39%) was born outside the US.

**FIGURE 7.** Percentage of individuals diagnosed with HIV infection by exposure mode and race/ethnicity, Massachusetts 2021 – 2023[[34]](#footnote-35)

The figure is a bar chart displaying the distribution of recent HIV diagnoses by exposure mode for each of three racial/ethnic groups: (N=437), Black NH (N=503), Hispanic/Latinx (N=434).


While the predominant exposure mode among White (non-Hispanic) and Hispanic/Latinx individuals recently diagnosed with HIV infection was MSM (44% and 53%, respectively), the largest proportion of Black (non-Hispanic) individuals was assigned no identified risk for exposure mode (39%). Of the Black NH individuals assigned NIR, 75% (N=148/198) were non-US born.

*HIV does not affect all Massachusetts residents equally. One way to understand which populations are experiencing differential impacts is to compare rates of HIV diagnosis per 100,000 population.*

**FIGURE 8.** Average annual age-adjusted HIV diagnosis rates per 100,000 population[[35]](#footnote-36) by sex assigned at birth and race/ethnicity, Massachusetts 2021 – 2023 (N=1,435)

The figure is a bar chart displaying the average annual HIV diagnosis rates per 100,000 among individuals assigned male at birth, individuals assigned female at birth, and the Massachusetts total population for four racial/ethnic groups: White NH, Black NH, Hispanic/Latinx, and Asian/Pacific Islander.


Figure 8 Note: \*\*Rates based on numerators <12 are marked with an asterisk (\*\*) and should be interpreted with caution.

In 2021 – 2023,[[36]](#footnote-37) the average annual age-adjusted HIV diagnosis rate per 100,000 population of individuals assigned male at birth (AMAB) was three times that of individuals assigned female at birth (AFAB). There were large disparities in average annual age-adjusted HIV diagnosis rates for 2021 to 2023 by race/ethnicity. Compared to the rate among White (non-Hispanic) individuals, the rate among:

* Black (non-Hispanic) individuals was 11 times greater, and
* Hispanic/Latinx individuals was five times greater.

With respect to differences based on race/ethnicity and sex assigned at birth, the average annual age-adjusted HIV diagnosis rate for 2021 to 2023 among:

* Black (non-Hispanic) individuals assigned male at birth (AMAB) was seven times that of White (non-Hispanic) individuals AMAB,
* Hispanic/Latinx individuals AMAB was five times that of White (non-Hispanic) individuals AMAB,
* Black (non-Hispanic) individuals assigned female at birth (AFAB) was 24 times that of White (non-Hispanic) individuals AFAB, and
* Hispanic/Latinx individuals AFAB was five times that of White (non-Hispanic) individuals AFAB.

# PERSONS LIVING WITH HIV INFECTION

*Who is currently living with HIV infection? The number of persons living with HIV infection (PLWH) reflects the impact of HIV in Massachusetts.*

**FIGURE 9.** Percentage of PLWH by current gender, age, race/ethnicity, and exposure mode, Massachusetts 2023[[37]](#footnote-38) (N=24,119)

The figure is a series of bar charts displaying the distribution of persons living with HIV infection by current gender, age, race/ethnicity, and exposure mode.


Racial/ethnic disparities persist among PLWH, and marked differences exist by current gender, age, and exposure mode. PLWH in Massachusetts are predominantly male (70%), older (36% aged 60+ years), and White non-Hispanic (38%). Male-to-male sex was the most frequently reported exposure mode, at 40%.

**FIGURE 10.** Percentage of PLWH by race/ethnicity and place of birth, Massachusetts 2023

The figure is a stacked bar chart displaying the distribution of persons living with HIV infection by place of birth (non-US, Puerto Rico/US Dependency, or US) for each of four racial/ethnic groups: White NH (N=9,053), Black NH (N=7,370), Hispanic/Latinx (N=6,764) and Asian/Pacific Islander (N=603).


Figure 10 Note: ii 98% of PLWH on 12/31/2023 who were born in a US dependency were born in Puerto Rico

A total of 77% of Asian/Pacific Islander PLWH in Massachusetts in 2023 were born outside the US, compared to 55% of Black (non-Hispanic), 37% of Hispanic/Latinx, and 9% of White (non-Hispanic) PLWH. An additional 32% of Hispanic/Latinx PLWH were born in Puerto Rico/US Dependencies.

**FIGURE 11.** Percentage of persons living with HIV infection (PLWH) by race/ethnicity, age, exposure mode, and place of birth by sex assigned at birth, Massachusetts 2023[[38]](#footnote-39)

(**Assigned Male at Birth, N= 17,103; Assigned Female at Birth, N= 7,016**)

The figure is a series of bar charts displaying a comparison of the distribution of persons living with HIV infection for individuals assigned male at birth (AMAB) and individuals assigned female at birth (AFAB) by race/ethnicity, age, exposure mode, and place of birth.


The distributions of PLWH by race/ethnicity, exposure mode, and place of birth varied by sex assigned at birth: the largest proportion of individuals assigned male at birth (AMAB) living with HIV infection was White (non-Hispanic) (44%), while the largest proportion of individuals assigned female at birth (AFAB) was Black (non-Hispanic) (48%). MSM (56%) was the predominant exposure mode among individuals AMAB compared to heterosexual sex (33%) and presumed heterosexual sex (32%) among individuals AFAB. A larger proportion of individuals AFAB (45%) than AMAB (28%) was born outside the US.

**FIGURE 12.** Percentage of PLWH by exposure mode and race/ethnicity, Massachusetts 2023[[39]](#footnote-40)

The figure is a bar chart displaying the distribution of persons living with HIV infection by exposure mode for each of three racial/ethnic groups: White NH (N=9,053), Black NH (N=7,370), Hispanic/Latinx (N=6,764).


The predominant exposure mode among White (non-Hispanic) PLWH was MSM (60%). Among Black (non-Hispanic) PLWH, the largest proportion was reported with no identified risk (28%), followed by heterosexual sex (20%), presumed heterosexual sex (20%), and MSM (19%). Among Hispanic/Latinx PLWH, the largest proportion was MSM (35%), followed by IDU (21%).

**FIGURE 13.** Age-adjusted HIV prevalence rates per 100,000 population[[40]](#footnote-41) by sex assigned at birth and race/ethnicity, Massachusetts 2023 (N=24,119)

The figure is a bar chart displaying the age-adjusted HIV prevalence rates per 100,000 population among individuals assigned male at birth, individuals assigned female at birth, and the Massachusetts total population for four racial/ethnic groups: White NH, Black NH, Hispanic/Latinx, and Asian/Pacific Islander.


In 2023, [[41]](#footnote-42) the age-adjusted HIV prevalence rate per 100,000 population of individuals assigned male at birth (AMAB) was three times that of individuals assigned female at birth (AFAB). There were large disparities in age-adjusted prevalence rates by race/ethnicity. Compared to the rate among White (non-Hispanic) individuals, the rate among:

* Black (non-Hispanic) individuals was ten times greater, and
* Hispanic/Latinx individuals was six times greater.

With respect to differences based on race/ethnicity and sex assigned at birth, the age-adjusted HIV prevalence rate among:

* Black (non-Hispanic) individuals AMAB was seven times that of White (non-Hispanic) individuals AMAB,
* Hispanic/Latinx individuals AMAB was six times that of White (non-Hispanic) individuals AMAB,
* Black (non-Hispanic) individuals AFAB was 27 times that of White (non-Hispanic) individuals AFAB, and
* Hispanic/Latinx individuals AFAB was 11 times that of White (non-Hispanic) individuals AFAB.

# MORTALITY AMONG INDIVIDUALS WITH HIV

*Who is dying with HIV and how has this changed over time?*

In 2023,[[42]](#footnote-43) 53 deaths among Massachusetts residents were attributed to HIV-related causes (generally, opportunistic illnesses, for a full list of stage-3 defining opportunistic illnesses, see: [https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm#Appendix](https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm)). Forty-three percent (N=23/53) of HIV-related deaths were among White (non-Hispanic) individuals, 26% (N=14/53) were among both Hispanic/Latinx and Black (non-Hispanic) individuals. Hispanic/Latinx and Black (non-Hispanic) Massachusetts residents died from HIV-related causes at younger ages (average ages of death were 56.2 and 56.7, respectively) compared to White non-Hispanic residents (average age of death was 63.5 years).[[43]](#footnote-44)

**FIGURE 14.** Average annual age-adjusted death rates among individuals reported with HIV per 100,000 population[[44]](#footnote-45) by sex assigned at birth and race/ethnicity, Massachusetts 2021–2023 (Total number of deaths among individuals reported with HIV from 2021–2023=1,024)

**The figure is a bar chart displaying the average annual age-adjusted death rate (2021-2023) among individuals reported with HIV per 100,000 for Massachusetts total, individuals assigned male at birth, individuals assigned female at birth, White NH individuals, Black NH individuals, and Hispanic/Latinx individuals.
**

**Age-Adjusted Rates**

In 2021 – 2023, the average annual age-adjusted death rate per 100,000 population for individuals assigned male at birth reported with HIV was three times that for individuals assigned female at birth. There were also large disparities in death rates by race/ethnicity: the rates among Black (non-Hispanic) individuals and Hispanic/Latinx individuals were eight and six times that of White (non-Hispanic) individuals, respectively.

**Age at Death**

The average age at death among individuals reported with HIV increased by 6.3 years, from 53.8 years in 2014 to 60.1 years in 2023.[[45]](#footnote-46) For comparison, the average age at death of the general Massachusetts population remained between 75.1 and 76.8 from 2014 to 2023.[[46]](#footnote-47)

**FIGURE 15.** Deaths among individuals reported with HIV by exposure mode, Massachusetts 2023 (N=307)

The figure is an open pie chart which displays the distribution by exposure mode of deaths among individuals reported with HIV/AIDS for 2023. A text box in the center of the pie chart reads, “40% reported IDU".


**Exposure Mode**

Individuals with IDU exposure mode accounted for the largest proportion of deaths among individuals reported with HIV. In 2023, 32% of deaths among individuals with HIV were reported with an exposure mode of IDU and an additional 8% were reported with an exposure mode of MSM/IDU, compared to 7% and 3%, respectively, of 2023 HIV infection diagnoses. The leading causes of death among individuals reported with HIV infection with IDU and IDU/MSM exposure mode who died in 2022 (with a known cause) were external causes of injuries[[47]](#footnote-48) and poisonings (which includes opioid overdoses) which accounted for 36% (N=53/147) of deaths, HIV which accounted for 16% (N=23/147) of deaths, cancer which accounted for 11% (N=16/147) of deaths, and heart disease which accounted for 8% (N=12/147) (*final cause of death is not yet available for all 2023 deaths among individuals with HIV as of 7/1/2024*).

**Survival among individuals diagnosed with AIDS**

**FIGURE 16.** Five-year survival among individuals with AIDS by year of diagnosis, Massachusetts 1989–2023 (Total number of AIDS diagnoses from 1989–2023, N=23,861)

The figure is a trendline that displays the percent of individuals alive less than 1, 1, 2, 3, 4, and 5 years after AIDS diagnosis for 7 cohorts by year of AIDS diagnosis: 1989-1993, 1994-1998, 1999-2003, 2004-2008, 2009-2013, 2014-2018, 2019-2023.


Survival of individuals diagnosed with AIDS has increased over time. In the earliest cohort of AIDS diagnoses (1989–1993), estimated survival at five years after AIDS diagnosis was 26%, compared to 88% in the most recent cohort (2019–2023). [[48]](#footnote-49)

**Trends in Age-Adjusted Rates of Death**

**FIGURE 17.** Age-adjusted rate of death per 100,000 population[[49]](#footnote-50) among individuals reported with HIV by sex assigned at birth, Massachusetts 2014–2023 (Total number of deaths among individuals reported with HIV from 2014–2023=3,167)

**The figure is a trendline displaying the age-adjusted rate of death per 100,000 population among individuals reported with HIV/AIDS for 2014 to 2023 for three groups: individuals assigned male at birth, individuals assigned female at birth, and the total population.
**

Over the last 10 years of available data, the age-adjusted rate of death per 100,000 population of individuals assigned male at birth (AMAB) reported with HIV has remained 2.5 to 3.5 times that of individuals assigned female at birth (AFAB). In 2023,[[50]](#footnote-51) the age-adjusted rate of individuals AMAB (5.2 per 100,000) was 2.8 times the rate of individuals AFAB (1.9 per 100,000).

**TRENDS IN DEATHS AMONG INDIVIDUALS WITH HIV**

The leading non HIV-related causes of death among individuals reported with HIV infection who died in 2022 (with a known cause) were external causes of injuries[[51]](#footnote-52) and poisonings (which includes opioid overdoses) which accounted for 26% (N=91/355) of deaths, cancer which accounted for 16% (N=57/355) of deaths, and heart disease which accounted for 11% (N=40/355) of deaths (*final cause of death is not yet available for all 2023 deaths as of 7/1/2024*).

**FIGURE 18.** Trends in all-cause deaths among individuals reported with HIV, Massachusetts 2014–2023

|  |  |  |
| --- | --- | --- |
| **All-Cause Deaths** | **2014** | **2023** |
| **Total** | 279 | 307 |
| **Sex Assigned at Birth** |  |  |
| Assigned Male Sex | 214 | 224 |
| Assigned Female Sex | 65 | 83 |
| **Race/Ethnicity** |  |  |
| White NH | 133 | 143 |
| Black NH | 73 | 86 |
| Hispanic/Latinx | 69 | 74 |
| API | 1 | 1 |
| Other/Unknown | 3 | 3 |
| **Age Group (Years)** |  |  |
| 0-12 | 0 | 0 |
| 13-19 | 0 | 0 |
| 20-29 | 8 | 4 |
| 30-39 | 18 | 17 |
| 40-49 | 60 | 23 |
| 50-59 | 122 | 90 |
| 60-69 | 54 | 120 |
| 70+ | 17 | 53 |
| **Exposure Mode** |  |  |
| MSM | 81 | 94 |
| IDU | 116 | 99 |
| MSM/IDU | 15 | 24 |
| HTSX | 20 | 27 |
| Other[[52]](#footnote-53) | 4 | 4 |
| Pres. HTSX | 15 | 19 |
| NIR | 28 | 40 |
| **Place of Birth** |  |  |
| US | 206 | 246 |
| PR/USD[[53]](#footnote-54) | 47 | 29 |
| Non-US | 26 | 32 |

**Overall**

The number of deaths due to any cause among individuals reported with HIV infection increased by 32% from 279 in 2014 to a peak of 367 in 2022, and then decreased by 16% to 307 in 2023. [[54]](#footnote-55)

**By Sex Assigned at Birth**

The annual number of deaths increased among individuals AFAB (by 28% from 65 to 83) and AMAB (by 5% from 214 to 224).

**By Race/Ethnicity**

The annual number of deaths increased among Black (non-Hispanic) individuals (by 18% from 73 to 86), White (non-Hispanic) individuals (by 8% from 133 to 143), and Hispanic/Latinx individuals (by 7% from 69 to 74).

**By Age at Death**

There was only one death among the youngest age groups (0–12 and 13–19) over the ten-year period and less than ten per year among the 20–29 year age group (except for 2019 when there were 12). Deaths decreased among the 40–49 year age group (by 62% from 60 to 23) and the 50–59 year age group (by 26% from 122 to 90). Deaths remained stable among the 30–39 year age group (from 18 to 17), more than doubled among the 60–69 year age group (from 54 to 120), and more than tripled among the 70+ year age group (from 17 to 53).

**By Exposure Mode**

Deaths increased among individuals with MSM/IDU (by 60%, from 15 to 24), no identified risk (by 43%, from 28 to 40), heterosexual (by 35%, from 20 to 27), presumed heterosexual (by 27%, from 15 to 19), and MSM (by 16%, from 81 to 94) and exposure modes. Deaths decreased among individuals with IDU exposure mode (by 15% from 116 to 99) and remained stable among individuals with other exposure modes.

**By Place of Birth**

Deaths increased among individuals born outside the US (by 23%, from 26 to 32), and in the US (by 19%, from 206 to 246), and decreased among individuals born in Puerto Rico/US dependencies (by 38%, from 47 to 29).

**FIGURE 19.** Trends in causes of death among individuals reported with HIV infection, Massachusetts 2014–2022 (N=2,528)[[55]](#footnote-56)

The figure is a stacked bar chart displaying the number of deaths by cause of death for each year from 2013 to 2021. Six causes of death are included in the chart: HIV, COVID-19, External causes of injuries and poisonings, Cancer, Heart disease, and All other causes. 
**Trends in Causes of Death**

The proportion of deaths among individuals reported with HIV infection attributed to HIV-related causes decreased from 28% (N=43/155) in 2014 to 16% (N=57/355) in 2022.[[56]](#footnote-57)

The proportion of deaths among individuals reported with HIV infection attributed to HIV-related causes decreased from 28% (N=43/155) in 2014 to 16% (N=57/355) in 2022.i

In 2022, 26% (N=91/355) of deaths were attributable to external causes of injuries[[57]](#footnote-58) and poisonings (which includes opioid overdoses),followed by cancer and HIV which both accounted for 16% (N=57/355), and heart disease which accounted for 11% (N=40/355). While COVID-19 was the third leading cause of death among persons reported with HIV infection in 2020, it was the sixth leading cause of death in 2022, accounting for 5% (N=16/355) of deaths in that year. By comparison, the leading causes of death in 2022 among the general population of Massachusetts were cancer which accounted for 26% (N=12,424/61,216) of deaths, heart disease which accounted for 25% (N=12,409/61,216), unintentional injuries[[58]](#footnote-59) which accounted for 10% (N=4,772/61,216), and stroke which accounted for 5% (N=2,391/61,216).[[59]](#footnote-60)

# GEOGRAPHIC DISTRIBUTION OF HIV INFECTION

*What is the geographic distribution of the HIV epidemic in Massachusetts?*

**FIGURE 20.** Percentage distributions of 2021–2023 HIV infection diagnoses (N=1,435) and 2023 persons living with HIV infection (PLWH, N=24,119) by Health Service Region (HSR), Massachusetts

The figure is a series of bar charts showing the percentage distribution of recent HIV diagnoses and people living with HIV infection by health service region.


Figure 20 Note: \*HSRs are regions defined geographically to facilitate focused health service planning. While prisons are not an HSR, the prison population is presented separately in this analysis because of its unique service planning needs. The prisons category represents persons who were diagnosed with HIV infection while in a correctional facility. As these data do not reflect current incarceration status, the category is not included for persons living with HIV infection.

The greatest proportion of new HIV infection diagnoses in 2021 – 2023[[60]](#footnote-61) was among residents of the Boston HSR (27%), followed by the Northeast HSR (19%), the Southeast HSR (18%), and the Metro West HSR (15%). Similar geographic distributions were observed for persons living with HIV infection (PLWH). The Boston HSR had the highest proportion of PLWH in 2023 (26%), followed by the Northeast HSR (18%), the Southeast HSR (17%), and the Metro West HSR (16%).

**FIGURE 21.** Percentage distribution of HIV infection diagnoses by Health Service Region (HSR) and exposure mode, Massachusetts 2021–2023 (N=1,405)

The figure is a bar chart displaying the percentage distribution of recent HIV diagnoses by exposure mode for each of six health service regions: Boston, Central, MetroWest, Northeast, Southeast, and Western.


MSM was the most frequently reported exposure mode in all regions of Massachusetts for individuals diagnosed with HIV infection during 2021 to 2023, [[61]](#footnote-62) accounting for 50% of diagnoses in the Western HSR, 44% in the Metro West HSR, 40% in the Central HSR, 39% in the Northeast HSR, 38% in the Boston HSR, and 34% in the Southeast HSR. The Boston HSR had the highest proportion of individuals with IDU exposure mode at 16%, followed by the Central HSR at 14%. IDU accounted for 5% to 9% of HIV infection diagnoses in the remaining regions.

**FIGURE 22.** Percentage distribution of HIV infection diagnoses by Health Service Region (HSR) and race/ethnicity, Massachusetts 2021–2023 (N=1,405)

The figure is a bar chart displaying the percentage distribution of recent HIV diagnoses by race/ethnicity for each of six health service regions: Boston, Central, MetroWest, Northeast, Southeast, and Western.


The Southeast and Central HSRs had the highest proportions of recent HIV infection diagnoses (2021–2023i) among White (non-Hispanic) individuals at 38% and 37%, respectively, while the Southeast HSR had the highest proportion among Black non-Hispanic individuals at 46%, and the Northeast HSR had the highest proportion among Hispanic/Latinx individuals at 39%.

**FIGURE 23.** Average annual age-adjusted rate of HIV infection diagnosis per 100,000 population by county, Massachusetts 2021–2023


The figure is a bar chart that displays the average annual rate of HIV diagnosis per 100,000 population for all Massachusetts counties: Barnstable/Dukes/Nantucket (6.4), Berkshire (3.9), Bristol (6.3), Essex (6.2), Franklin (2.7), Hampden (7.7), Hampshire (2.7), Middlesex (5.1), Norfolk (4.4), Plymouth (7.5), Suffolk (14.7), and Worcester (6.0). 


Figure 23 Note: \*Rates based on numerators <12 are marked with an asterisk (\*) and should be interpreted with caution. Barnstable, Dukes, and Nantucket Counties are combined because of small numbers.

Suffolk County, in which Boston is the biggest city, was selected as one of 48 counties nationally that was prioritized for funding in the U.S. Department of Health and Human Services’ initiative “Ending the HIV Epidemic (EHE): A Plan for America”. This is a ten-year initiative beginning in 2020 to achieve a 75% reduction in new HIV infections in five years and at least a 90% reduction in ten years. For more information about EHE, see <https://www.hrsa.gov/ending-hiv-epidemic> and <https://jri.org/ending-the-hiv-epidemic-in-Massachusetts> for the Suffolk County EHE Plan. Suffolk County had the highest average age-adjusted rate of HIV infection diagnosis during 2021 to 2023 among all Massachusetts counties at 14.7 per 100,000, as well as the highest prevalence rate of persons living with HIV infection in 2023 at 783.2 per 100,000. [[62]](#footnote-63)

**FIGURE 24.** Average annual rate of HIV infection diagnosis per 100,000 population[[63]](#footnote-64) by city/town, Massachusetts 2021–2023




Figure 24 note: Regional HIV diagnosis data exclude individuals diagnosed in a correctional facility.

The cities and towns with the highest average annual rate of HIV infection diagnosis during 2021 to 2023[[64]](#footnote-65) included Brockton (23.7 per 100,000), Boston (17.3), Chelsea (17.2), Malden (14.6), and Lynn (14.5).[[65]](#footnote-66) Boston had the highest number of new HIV infection diagnoses from 2021–2023 (N=351), followed by Brockton (N=75), and Worcester (N=70).

In early 2019, a new cluster of HIV infection was identified in Boston among PWID who were experiencing or had experienced recent homelessness. As of July 1, 2024, a total of 213 cases diagnosed since November 2018 have been investigated and identified as part of the Boston cluster. Emerging trends among those newly diagnosed in the Boston cluster (N=15 cases diagnosed in 2023) include an increase in polysubstance and methamphetamine use.[[66]](#footnote-67)

**FIGURE 25.** Prevalence rate of persons living with HIV infection (PLWH) per 100,000 population by city/town, Massachusetts 2023[[67]](#footnote-68)

The figure is a rate map of Massachusetts displaying the HIV prevalence rate per 100,000 population by city/town. Cities and towns are in one of six categories: no reported cases, less than 80.8 per 100,000, 80.8-117.6 per 100,000, 117.7-164.0 per 100,000, 164.1-253.3 per 100,000, or greater than 253.3 per 100,000.


Figure 25 note: Regional HIV data may include PLWH who may have been incarcerated in 2023.

The cities and towns in Massachusetts with the highest prevalence rate of PLWH in 2023 included Provincetown (12,259.0 per 100,000), Shirley (847.8), Springfield (845.9), Boston (836.4), and Ayer (790.2).[[68]](#footnote-69) Boston and Springfield had the highest numbers of PLWH in 2023, at 5,651 and 1,319, respectively.

# HIV CARE CONTINUUM – NEWLY DIAGNOSED

**FIGURE 26.** Stages of HIV care among individuals newly diagnosed with HIV infection in Massachusetts, 2022 (N=419)

**The figure is a bar chart displaying the percentage of individuals newly diagnosed with HIV infection in Massachusetts in 2022 who were linked to care (89%), retained in care (85%), and virally suppressed (83%). 
**

**FIGURE 27.** Viral load status among individuals newly diagnosed with HIV infection in Massachusetts, 2022 (N=419)

The figure is a pie chart indicating the proportion of individuals who were newly diagnosed with HIV infection in 2022 who were virally suppressed (83%), missing viral load data (4%), or for whom viral load was not suppressed (13%). NOTE: Missing viral load data includes individuals who have not had a lab reported in the past year.


Figure 27 Note: Missing Viral Load Data includes individuals who had not had a lab reported in the 12-month period after diagnosis.

Among 419 individuals newly diagnosed with HIV infection in 2022 (and alive in Massachusetts through 2023),[[69]](#footnote-70) 83% were virally suppressed, 13% were not virally suppressed, and 4% did not have a viral load test in the year after diagnosis. Among those newly diagnosed individuals who were linked to care (N=372) and retained in care (N=358), rates of viral suppression were higher at 90% and 93%, respectively. Among individuals diagnosed with HIV infection in 2022, timely linkage to care differed by race/ethnicity and exposure mode. Viral suppression was lowest among individuals with IDU and MSM/IDU exposure modes (54% and 73%, respectively, compared to 85% to 96% among other exposure modes).[[70]](#footnote-71)

**FIGURE 28.** Linkage to care among individuals newly diagnosed with HIV infection by sex assigned at birth, race/ethnicity, age, and exposure mode, Massachusetts 2022 (N=419)[[71]](#footnote-72)

The figure is a bar chart which displays the percentage of individuals who were linked to care among those newly diagnosed with HIV infection by: sex assigned at birth (individuals AMAB and AFAB), race/ethnicity (White NH, Black NH, and Hispanic/Latinx individuals); age at diagnosis (individuals aged 0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and aged 70+ years), and exposure mode (individuals with MSM, IDU, MSM/IDU, HTSX, Pres. HTSX, and NIR exposure modes).


**FIGURE 29.** Viral suppression among individuals newly diagnosed with HIV infection by sex, race/ethnicity, age, and exposure mode, Massachusetts 2022 (N=419)

The figure is a bar chart which displays the percentage of individuals who were virally suppressed among those newly diagnosed with HIV infection by: sex assigned at birth (individuals AMAB and AFAB), race/ethnicity (White NH, Black NH, and Hispanic/Latinx individuals); age at diagnosis (individuals aged 0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and aged 70+ years), and exposure mode (individuals with MSM, IDU, MSM/IDU, HTSX, Pres. HTSX, and NIR exposure modes).
Figure 28 and 29 Note: \*Percentages based on numerators <5 are marked with an asterisk (\*) and should be interpreted with caution

# HIV CARE CONTINUUM – PLWH

**FIGURE 30.** Stages of HIV care among persons living with HIV infection in Massachusetts, 2023 (N=22,837)

The figure is a bar chart displaying the percentage of individuals living with HIV infection in Massachusetts in 2023 who were engaged in care (71%), retained in care (44%), and virally suppressed (64%). 


**FIGURE 31.** Viral load status among persons living with HIV infection in Massachusetts, 2023 (N=22,837)

The figure is a pie chart indicating the proportion of individuals who were living with HIV infection in 2023 who were virally suppressed (64%), missing viral load data (32%), or for whom viral load was not suppressed (4%). NOTE:  Missing Viral Load Data includes individuals who have not had a lab reported in the past year.



Figure 31 Note: Missing Viral Load Data includes individuals who had not had a lab reported in the past year

Among 22,837 persons living with HIV infection (PLWH) in Massachusetts at the end of 2023(and diagnosed through 2022),[[72]](#footnote-73) 64% were virally suppressed, 4% were not virally suppressed, and 32% did not have a viral load test in 2023. Rates of care engagement and retention were lower in 2023 (71% and 44%, respectively), 2022 (71% and 43%, respectively), 2021 (72% and 45%, respectively) and 2020 (69% and 39%, respectively) than in 2019 (75% and 54% respectively), likely due to the effects of the COVID-19 pandemic. However, please note that the total number of PLWH used to calculate these rates includes all individuals who have ever been diagnosed with HIV infection in Massachusetts with no evidence of death or having moved out of the state or country. Quality assurance efforts are currently being conducted to update the number of PLWH used for this analysis. Among those PLWH who were engaged in care (N=16,104) and retained in care (N=10,116), rates of viral suppression were higher at 91% and 95%, respectively. In 2023, engagement in care and viral suppression among PLWH differed slightly by age.[[73]](#footnote-74)

**FIGURE 32.** Engagement in care among persons living with HIV infection by sex assigned at birth, race/ethnicity, age, and exposure mode, Massachusetts 2023 (N=22,837)[[74]](#footnote-75)

**The figure is a bar chart which displays the percentage of individuals who were engaged in care among those living with HIV infection by: sex assigned at birth (individuals AMAB and AFAB), race/ethnicity (White NH, Black NH, and Hispanic/Latinx individuals); current age (individuals aged 0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and aged 70+ years), and exposure mode (individuals with MSM, IDU, MSM/IDU, HTSX, Pres. HTSX, and NIR exposure modes).
**

**FIGURE 33.** Viral suppression among persons living with HIV infection by sex assigned at birth, race/ethnicity, age, and exposure mode, Massachusetts 2023 (N=22,837)

The figure is a bar chart which displays the percentage of individuals who were virally suppressed among those living with HIV infection by: sex assigned at birth (individuals AMAB and AFAB), race/ethnicity (White NH, Black NH, and Hispanic/Latinx individuals); current age (individuals aged 0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and aged 70+ years), and exposure mode (individuals with MSM, IDU, MSM/IDU, HTSX, Pres. HTSX, and NIR exposure modes).



**FIGURE 34.** Viral suppression among persons living with HIV infection engaged in care by sex assigned at birth, race/ethnicity, age, and exposure mode, Massachusetts 2023 (N=16,104)

The figure is a bar chart which displays the percentage of individuals who were virally suppressed among those living with HIV infection and engaged in care by: sex assigned at birth (individuals AMAB and AFAB), race/ethnicity (White NH, Black NH, and Hispanic/Latinx individuals); current age (individuals aged 0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and aged 70+ years), and exposure mode (individuals with MSM, IDU, MSM/IDU, HTSX, Pres. HTSX, and NIR exposure modes).


Among 16,104 persons living with HIV infection (PLWH) and engaged in care in Massachusetts at the end of 2023, [[75]](#footnote-76) viral suppression did not differ substantially by sex assigned at birth, race/ethnicity, age or exposure mode.

# SOCIAL VULNERABILITY INDEX

*The social vulnerability index (SVI)[[76]](#footnote-77) is a tool to identify socially vulnerable communities that was created by CDC and the Agency for Toxic Substances and Disease Registry (ATSDR). The CDC/ATSDR SVI uses U.S. Census data to determine the social vulnerability of every census tract. The SVI ranks each tract on 16 social factors, including poverty, lack of vehicle access, and crowded housing, and groups them into four related themes: socioeconomic status, household characteristics, racial and ethnic minority status, and housing type/transportation. Each census tract receives a separate ranking for each of the four themes, as well as an overall ranking. Originally developed to incorporate social determinants of health into emergency response and recovery efforts for environmental and natural disasters, more recently, higher SVI has been linked to higher HIV diagnosis rates,[[77]](#footnote-78) COVID-19 mortality, and lower COVID-19 vaccination coverage.[[78]](#footnote-79)*

**FIGURE 35.** HIV infection diagnoses by Social Vulnerability Index\*, Massachusetts 2021–2023

The figure is a stacked bar chart displaying the distribution of HIV infection diagnoses by the social vulnerability index. The distribution of social vulnerability by six categories (high, moderately high, moderately low, low, homeless, other/unknown) is displayed for each year. 


Figure 35 Notes: \* Census tract level overall SVI values for 2020 were obtained from CDC/Agency for Toxic Substance and Disease Registry (CDC/ATSDR) and assigned to all cases based on their street address at diagnosis. Values range from 0 to 1, with higher values implying greater social vulnerability. SVI rankings were grouped into quartiles (low, <0.25; mid low, 0.25 - <0.5; mid high, 0.5 - <0.75; high >0.75).

ⱡ Other/Unknown includes correctional facility addresses, P.O. Box addresses, hospital addresses, and addresses that could not be geocoded

**Social Vulnerability Index**

The majority of individuals recently diagnosed with HIV infection in Massachusetts were diagnosed in areas with high (51% in 2023) or moderately high (23% in 2023) social vulnerability. [[79]](#footnote-80)

# TECHNICAL NOTES

1. **Data source for all HIV case data:**

Massachusetts Department of Public Health (DPH) Bureau of Infectious Disease and Laboratory Sciences (BIDLS) HIV Surveillance Program. Data are current as of 7/1/2024 and may be subject to change.

## **Individuals diagnosed with HIV infection:**

New HIV diagnoses include only individuals who were first diagnosed in Massachusetts. HIV diagnoses data reflect the year of HIV infection diagnosis among all individuals reported with HIV infection, with or without an AIDS diagnosis, for the most recently available three-year (2021–2023) or ten-year (2014–2023) period.

1. **Individuals living with HIV infection by current residence:**

## As of January 1, 2018, the Massachusetts Department of Public Health (MDPH) Bureau of Infectious Disease and Laboratory Sciences (BIDLS) HIV fact sheets, epidemiologic reports, and other HIV data presentations include all individuals living with HIV infection who are currently residing in Massachusetts. These prevalent cases include those who may have been first diagnosed in another state. Reports of incidence or new diagnoses will continue to include only individuals who are first diagnosed in Massachusetts. Please note that HIV fact sheets, data reports, and presentations published from 2011 to 2017 include only cases that were first diagnosed in Massachusetts. BIDLS service planning continues to ensure responsive services to the entire population living with HIV infection in Massachusetts, regardless of place of diagnosis.

## **Individuals diagnosed with AIDS:**

## AIDS diagnoses include only individuals who were first diagnosed in Massachusetts for the most recently available three-year (2021–2023) or ten-year (2014–2023) period.

## **Individuals born in Puerto Rico or other US Dependencies (American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin Islands)**

94% of individuals diagnosed with HIV infection (HIV DX) from 2021–2023, 99% of individuals diagnosed with HIV infection from 2014–2023, 98% of persons living with HIV infection on 12/31/2023, 99% of individuals diagnosed with AIDS from 2014–2023, 99% of individuals who died from 2021–2023, and 99% of individuals who died from 2014–2023 who were born in a US dependency were born in Puerto Rico.

1. **Individuals born outside the US (non-US born)**

Individuals born outside the US (non-US born) excludes individuals born in the United States, Puerto Rico, American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin Islands.

## **Gender**

Current gender data present number and percentage distributions of HIV surveillance data for cisgender (persons whose current gender identity corresponds with their sex assigned at birth) and transgender individuals. Please note that reported numbers among transgender individuals are likely to be underestimates due to underreporting of current gender.

## **Configuration of Health Service Regions (HSR)**

For HIV and AIDS diagnoses, residence is at diagnosis. For individuals living with HIV infection and deaths, residence is based on the most recent record available. Definitions of Health Service Regions can be found at: [Health Services Regions.](https://www.mass.gov/info-details/massgis-data-ma-executive-office-of-health-human-services-regions#:~:text=The%20regions%20%2D%20Western%2C%20Central%2C,and%20towns%20(see%20map))


## The figure is a map of Massachusetts displaying the location of each of the six health service regions: Boston, Central, Metrowest, Northeast, Southeast, and Western.

## **Prisons**

HSRs are regions defined geographically to facilitate targeted health service planning. While prisons are not an HSR, the prison population is presented separately because of its unique service planning needs. The prisons category represents persons who were diagnosed with HIV infection while in a correctional facility. As these data do not reflect current incarceration status, the category is not included for individuals living with HIV infection or deaths among individuals with HIV.

## **Configuration of Massachusetts cities/towns and counties**

For HIV and AIDS diagnoses, residence is at diagnosis. For individuals living with HIV infection and deaths, residence is based on the most recent record available.



1. **Age**

Age in years is at HIV diagnosis for individuals diagnosed with HIV infection, age on 12/31/2023 for individuals living with HIV infection, and age at death for individuals reported with HIV who died. Please note, pediatric HIV infections diagnosed under age 13 are reported by year of diagnosis; therefore, the annual number of pediatric diagnoses differs from the annual number of perinatal infections (among infants) that are reported by year of birth.

## **Background on HIV reporting system**

## Massachusetts Department of Public Health (MDPH) regulations started requiring healthcare providers to submit case report forms, with demographic and risk information, on individuals diagnosed with AIDS in 1983, and with HIV infection in 1999. Existing cases of HIV infection diagnosed through 1998 were also to be reported by the end of 1999. When comparing HIV infection diagnosed before 1999 to HIV infection diagnosed after 1999, users should consider the differences in HIV reporting requirements for these two time periods. Since HIV was not reported at diagnosis prior to 1999 and clinical providers were given a relatively short time frame within which to report all prevalent HIV cases, the pre-1999 data may be less complete than data reported after 1999. Additionally, pre-1999 HIV infection diagnoses do not include individuals who were diagnosed with HIV infection and who died before 1999 without being reported with AIDS, nor do they include individuals who were no longer receiving HIV-related health care in Massachusetts at the point when HIV (non-AIDS) reporting became mandatory.

Beginning in 2019, all new diagnoses of HIV infection were assigned to field epidemiologists for partner services, to ensure disease education/comprehension, and assist with linkage to HIV care. As a part of this process, field epidemiologists helped to collect pertinent epidemiological, demographic, and risk information of the individual.

1. **Data limitations**

While trends in new HIV diagnoses are the best indicator of those who are most at risk of HIV infection, HIV surveillance reflects only incident diagnoses among individuals who are in care and not the actual incidence of new infections. Individuals may be living with HIV infection for many years prior to being tested and seeking care, at which point the case is considered a “diagnosis” and reported to the MDPH Bureau of Infectious Disease and Laboratory Sciences. In the most recent years of data presented, delays may occur in the reporting of a case to MDPH after it is diagnosed. Although Massachusetts regulations require providers to submit HIV case reports in a timely fashion, some 2023 HIV infection diagnoses will be reported to the surveillance program after the release of this report. Thus, the 2023 data presented in this report may change slightly. Previous analyses of Massachusetts HIV case data have suggested that the distribution of HIV infection diagnoses by race/ethnicity, sex assigned at birth and exposure mode for cases reported more than 6 months after diagnosis was not substantially different than the distribution of HIV cases reported within 6 months. Caution should be exercised when considering changes in HIV diagnosis trends for 2023.

1. **Deaths among people reported with HIV**

## All-cause death data include only individuals who were first diagnosed with HIV in Massachusetts for the most recently available three-year (2021–2023) or ten-year (2014–2023) period.

The death data presented in this report include all deaths among people diagnosed and reported with HIV in Massachusetts to present a full description of trends in mortality among this population. This includes deaths from non-HIV related causes such as drug overdoses, suicides, motor vehicle accidents and other causes. Therefore, the total number of annual deaths reported here will vary from the number of HIV-related deaths reported in *Massachusetts Deaths* by the Massachusetts Department of Public Health, Office of Population Health (available at <https://www.mass.gov/lists/death-data>). The death data reported here are considered complete through 2022. Data on deaths occurring in Massachusetts are from matches with the Massachusetts Registry of Vital Records and Statistics and from provider reports. Data on deaths occurring outside of Massachusetts are from matches with the Social Security Death Master File.

1. **HIV primary exposure mode definitions**

The HIV primary exposure mode indicates the most probable risk behavior associated with HIV infection. Assignment of primary exposure mode is done in accordance with Centers for Disease Control and Prevention (CDC) guidelines when multiple exposure modes are reported. Although the reported primary exposure mode is the most likely mode of transmission, there is always the possibility that it is not the actual mode of transmission. Following is a description of the exposure mode categories:

* **MSM (Male-to-Male Sex):** Includes all individuals assigned male at birth who report any sexual contact with other individuals that identify as male. Please note that in accordance with CDC guidelines, this category is defined by an individual’s assigned sex at birth and not an individual’s current gender identity.
  + **Sex with Men:** This exposure mode category is used by the Bureau of Infectious Disease and Laboratory Sciences (BIDLS) to categorize sexual risk in transgender women reporting sex with men only. For the purposes of official reporting in the MA HIV Surveillance System and to CDC, exposure mode for transgender women is based on sex assigned at birth, and therefore would be reported as male-to-male sex.
* **IDU (Injection Drug Use):** Cases among persons who report injection drug use.
* **MSM/IDU:** Includes all individuals assigned male at birth who report both sexual contact with other individuals that identify as male and injection drug use.
  + **Sex with Men/IDU:** This exposure mode category is used by BIDLS to categorize sexual risk in transgender women reporting both sex with men and injection drug use. For the purposes of official reporting in the MA HIV Surveillance System and to CDC, exposure mode for transgender women is based on sex assigned at birth, and therefore would be reported as MSM/IDU.
* **Heterosexual Sex:** Cases among persons who report heterosexual sex with a person with, or at increased risk for, HIV infection (e.g., a person who injects drugs (PWID)). The sub-categories for this mode of transmission are listed below.

Heterosexual Sex w/ a person who injects drugs

Heterosexual Sex w/ a person w/ HIV infection or AIDS

Heterosexual Sex w/ bisexual male

Other Heterosexual Sex: includes all other sub-categories of heterosexual risk, such as heterosexual contact with a person infected through a blood transfusion.

* + - * + **Other:** Cases among persons with other known exposure modes, including receipt of clotting factor, receipt of transfusion or transplant, and mother-to-child transmission through pregnancy, childbirth, or breastfeeding (perinatal transmission).
        + **Presumed Heterosexual:** The presumed heterosexual risk category is used by BIDLS exclusively for individuals assigned female at birth to identify HIV exposure mode when sex with individuals that identify as male was the only reported risk factor, there was no evidence of current or past IDU, and behavioral risk and HIV status information about sexual partners that identify as male was unknown. The rationale for the application of the presumed heterosexual risk category to individuals assigned female at birth only has been addressed in the MDPH Office of HIV report “Intersecting Risks: HIV Infection among Heterosexual Women and Men in Massachusetts” (2010).
* **NIR (No Identified Risk):** Cases among persons with no reported history of exposure to HIV through any of the listed exposure categories. Follow-up is conducted to determine risk for those cases that are initially reported without a risk identified. Includes cases among individuals assigned male at birth who were previously categorized in Massachusetts as Presumed Heterosexual.

1. **Cell suppression methodology:**

Values one through four are suppressed for denominator populations less than 50,000 or for unknown population sizes. Additional values of zero and greater than or equal to five may be suppressed to prevent back calculation. Values less than five are not suppressed for unknown health service region or for compound categories (categories containing two or more subcategories, such as ‘other/undetermined’ race/ethnicity or ‘other’ exposure modes, which includes pediatric, blood, and blood product exposure modes), because the exact count of each subcategory cannot be determined.

1. **Population estimates used for rate calculations**

As of 1/1/2020, BIDLS calculates rates per 100,000 population using denominators estimated by the University of Massachusetts Donahue Institute using a modified Hamilton-Perry model. 2020 population estimates were used for single-year rates; for pooled year rates (i.e., 2019-2021), the 2020 population estimates were multiplied by three. For more information, see: Strate S, et al. Small Area Population Estimates for 2011 through 2020, report published Oct 2016, and <http://www.donahue.umassp.edu/business-groups/economic-public-policy-research/massachusetts-population-estimates-program>. Note that rates and trends calculated using previous methods cannot be compared to these.

1. **Rates based on numerators <12**

Rates based on numerators <12 are marked with an asterisk (\*) and should be interpreted with caution.

1. **Explanation of age-adjusted rates**

A rate of a disease per 100,000 population is a useful way to compare groups with substantially different population sizes rather than relying on the raw number of cases. For example, the number of individuals living with HIV infection (PLWH) on December 31, 2023 who are Hispanic/Latinx is 6,764, whereas the number of individuals living with HIV infection who are white (non-Hispanic) is 9,053. Although the *number* of individuals living with HIV infection who are Hispanic/Latinx in Massachusetts is smaller than the number of individuals living with HIV infection who are white (non-Hispanic), we also need to consider that there are far fewer individuals of Hispanic/Latinx heritage living in Massachusetts than white (non-Hispanic) individuals. Hispanic/Latinx individuals represent 12% of the Massachusetts population compared to white (non-Hispanic) individuals who represent 71% of the population. If HIV had the same impact on the Hispanic/Latinx population of the state as on the white (non-Hispanic) population, then there should be six times as many cases in white (non-Hispanic) individuals, but there are less than twice as many. By calculating a rate which takes into consideration the differences in the population size, it is evident that the number of individuals living with HIV infection for every 100,000 Hispanic/Latinx individuals in Massachusetts is much higher than the rate for every 100,000 white (non-Hispanic) individuals. This is called a "crude rate" and is calculated by dividing the number of individuals living with HIV infection by the population of interest (the total number of Hispanic/Latinx individuals in Massachusetts, for example) and multiplying by 100,000. (See example below.)

## Example: Calculation of crude HIV prevalence rate for white (non-Hispanic) individuals, Massachusetts (187.3 per 100,000)

|  |  |
| --- | --- |
| Crude HIV prevalence rate for white (non-Hispanic) individuals | = [number of white (non-Hispanic) individuals living with HIV infection ÷ population size of white (non-Hispanic) individuals] ×100,000 |
|  | = (9,053/4,832,394.52) ×100,000 |
|  | = (0.00187340) ×100,000 |
|  | = 187.3 |

However, sometimes, in addition to the population size being different, the age composition of the populations is different. In Massachusetts, the black (non-Hispanic) and Hispanic/Latinx populations are on average younger than white (non-Hispanic) population (medians: 29.7 years and 24.5 years vs. 38.8 years, respectively). Therefore, it is necessary to age-adjust the HIV prevalence rate to get a true comparison of the impact of the disease across racial/ethnic groups without an effect from the differences in age composition. Age-adjustment of rates minimizes the distortion created by differences in age composition. Age-adjusted rates are calculated by weighting the age-specific rates for a given population by the age distribution of a standard population. The weighted age-specific rates are then summed to produce the adjusted rate for all ages combined.

1. **HIV Care Continuum Indicator Definitions:**

* HIV care continuum among individuals newly diagnosed with HIV infection in Massachusetts: “Newly Diagnosed” includes individuals diagnosed in 2022, alive through 12/31/2023, and living in Massachusetts based on last known address. “Linked to Care” is defined as having ≥1 viral load (VL) or CD4 test result within 3 months of diagnosis. “Retained in Care” is defined as having ≥2 VL or CD4 test results at least 3 months apart during the 12-month period after diagnosis. “Virally Suppressed” is defined as having a VL <200 copies/mL for the most recent VL test drawn during the 12-month period after diagnosis.
* HIV care continuum among persons living with HIV infection (PLWH) in Massachusetts: “PLWH” refers to individuals diagnosed through 2022, alive through 12/31/2023, and living in Massachusetts based on last known address. “Engaged in Care” is defined as having ≥1 VL or CD4 test result in 2023. “Retained in Care” is defined as having ≥2 VL or CD4 test results at least 3 months apart in 2023. “Virally Suppressed” is defined as having a VL <200 copies/mL for the most recent VL test drawn in 2023.

1. **AIDS Progression**

Progression to AIDS refers to individuals diagnosed with HIV while living in Massachusetts who were later diagnosed with AIDS while living in Massachusetts. Individuals diagnosed with HIV or AIDS outside of Massachusetts are excluded. Individuals diagnosed with HIV and AIDS concurrently (AIDS diagnosis within 2 months of HIV diagnosis) are also excluded. Year refers to year of AIDS diagnosis.

1. Providers may use this number to report individuals newly diagnosed with a notifiable sexually transmitted infection, including HIV, or request partner services. Partner services is a free and confidential service for individuals recently diagnosed with a priority infection. The client-centered program offers counseling, linkage to other health and social services, anonymous notification of partners who were exposed and assistance with getting testing and treatment. For more information, see: [*https://www.mass.gov/service-details/partner-services-program-information-for-healthcare-providers*](https://www.mass.gov/service-details/partner-services-program-information-for-healthcare-providers))  [↑](#footnote-ref-2)
2. Source: Centers for Disease Control and Prevention and Health Resources and Services Administration. *Integrated Guidance for Developing Epidemiologic Profiles: HIV Prevention and Ryan White HIV/AIDS Program Planning*. Atlanta, Georgia: Centers for Disease Control and Prevention; 2022. [↑](#footnote-ref-3)
3. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-4)
4. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-5)
5. For more information, see: Charles Alpren et al. “Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs—Massachusetts, 2015–2018”, *American Journal of Public Health* 110, no. 1 (January 1, 2020): pp. 37-44. <https://doi.org/10.2105/AJPH.2019.305366> [↑](#footnote-ref-6)
6. For more information, see: Joint MDPH and BPHC Clinical Advisory: Increase in newly diagnosed HIV infections among persons who inject drugs in Boston, March 15, 2021, available at: <https://www.mass.gov/doc/joint-mdph-and-bphc-clinical-advisory-hiv-transmission-through-injection-drug-use-in-boston-march-15-2021/download> [↑](#footnote-ref-7)
7. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-8)
8. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-9)
9. External causes of injuries include intentional injuries (e.g., homicide and suicide), unintentional injuries (e.g., motor vehicle and non-transport related accidents), and injuries of undetermined intent. [↑](#footnote-ref-10)
10. Data Source for Massachusetts death data: Office of Population Health, Massachusetts Department of Public Health. Note: 2022 and 2023 death data are preliminary. [↑](#footnote-ref-11)
11. Among cities that reported at least 12 HIV infections during 2021-2023. [↑](#footnote-ref-12)
12. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-13)
13. Virally Suppressed” is defined as having a VL <200 copies/mL for the most recent VL test drawn during the 12-month period after diagnosis. [↑](#footnote-ref-14)
14. “Linked to Care” is defined as having ≥1 viral load (VL) or CD4 test result within 3 months of diagnosis. [↑](#footnote-ref-15)
15. “Retained in Care” is defined as having ≥2 VL or CD4 test results at least 3 months apart during the 12-month period after diagnosis. [↑](#footnote-ref-16)
16. “Virally Suppressed” is defined as having a VL <200 copies/mL for the most recent VL test drawn in 2023. [↑](#footnote-ref-17)
17. “Engaged in Care” is defined as having ≥1 VL or CD4 test result in 2023. [↑](#footnote-ref-18)
18. “Retained in Care” is defined as having ≥2 VL or CD4 test results at least 3 months apart in 2023. [↑](#footnote-ref-19)
19. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-20)
20. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-21)
21. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-22)
22. All individuals diagnosed with HIV infection from 2014-2023 with other exposure mode were pediatric exposures [↑](#footnote-ref-23)
23. 99% of individuals diagnosed with HIV infection from 2014–2023 who were born in a US dependency were born in Puerto Rico [↑](#footnote-ref-24)
24. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-25)
25. While the majority of pediatric exposures are confirmed perinatal exposures, this category also includes a small number of pediatric cases with insufficient documentation of maternal HIV status to confirm perinatal exposure. [↑](#footnote-ref-26)
26. For more information, see: Charles Alpren et al. “Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs—Massachusetts, 2015–2018”, *American Journal of Public Health* 110, no. 1 (January 1, 2020): pp. 37-44. <https://doi.org/10.2105/AJPH.2019.305366> and

    Joint MDPH and BPHC Clinical Advisory: Increase in newly diagnosed HIV infections among persons who inject drugs in Boston, March 15, 2021, available at: <https://www.mass.gov/doc/joint-mdph-and-bphc-clinical-advisory-hiv-transmission-through-injection-drug-use-in-boston-march-15-2021/download> [↑](#footnote-ref-27)
27. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-28)
28. All individuals diagnosed with HIV infection from 2014–2023 with other exposure mode were pediatric exposures [↑](#footnote-ref-29)
29. 99% of individuals diagnosed with HIV infection from 2014–2023 who were born in a US dependency (USD) were born in Puerto Rico (PR) [↑](#footnote-ref-30)
30. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-31)
31. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-32)
32. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-33)
33. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-34)
34. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-35)
35. As of 1/1/2020, BIDLS calculates rates per 100,000 population using denominators estimated by the University of Massachusetts Donahue Institute using a modified Hamilton-Perry model (Strate S, et al. Small Area Population Estimates for 2011 through 2020, report published Oct 2016). Note that rates and trends calculated using previous methods cannot be compared to these. All rates are age-adjusted using the 2000 US standard population. [↑](#footnote-ref-36)
36. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-37)
37. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-38)
38. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-39)
39. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-40)
40. As of 1/1/2020, BIDLS calculates rates per 100,000 population using denominators estimated by the University of Massachusetts Donahue Institute using a modified Hamilton-Perry model (Strate S, et al. Small Area Population Estimates for 2011 through 2020, report published Oct 2016). Note that rates and trends calculated using previous methods cannot be compared to these. All rates are age-adjusted using the 2000 US standard population. [↑](#footnote-ref-41)
41. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-42)
42. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-43)
43. Data Source for Massachusetts death data: Office of Population Health, Massachusetts Department of Public Health. Note: 2022 and 2023 death data are preliminary. [↑](#footnote-ref-44)
44. As of 1/1/2020, BIDLS calculates rates per 100,000 population using denominators estimated by the University of Massachusetts Donahue Institute using a modified Hamilton-Perry model (Strate S, et al. Small Area Population Estimates for 2011 through 2020, report published Oct 2016). Note that rates and trends calculated using previous methods cannot be compared to these. All rates are age-adjusted using the 2000 US standard population. [↑](#footnote-ref-45)
45. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-46)
46. Data Source for Massachusetts death data: Office of Population Health, Massachusetts Department of Public Health. Note: 2022 and 2023 death data are preliminary. [↑](#footnote-ref-47)
47. External causes of injuries include intentional injuries (e.g., homicide and suicide), unintentional injuries (e.g., motor vehicle and non-transport related accidents), and injuries of undetermined intent. [↑](#footnote-ref-48)
48. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-49)
49. As of 1/1/2020, BIDLS calculates rates per 100,000 population using denominators estimated by the University of Massachusetts Donahue Institute using a modified Hamilton-Perry model (Strate S, et al. Small Area Population Estimates for 2011 through 2020, report published Oct 2016). Note that rates and trends calculated using previous methods cannot be compared to these. All rates are age-adjusted using the 2000 US standard population. [↑](#footnote-ref-50)
50. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-51)
51. External causes of injuries include intentional injuries (e.g., homicide and suicide), unintentional injuries (e.g., motor vehicle and non-transport related accidents), and injuries of undetermined intent. [↑](#footnote-ref-52)
52. Other includes pediatric and clotting factor/transfusion/transplant-related exposures [↑](#footnote-ref-53)
53. Ninety-nine percent of individuals reported with HIV/AIDS who died from 2014–2023 who were born in a US dependency (USD) were born in Puerto Rico (PR) [↑](#footnote-ref-54)
54. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-55)
55. Deaths among individuals reported with HIV infection with a missing cause of death are excluded from this analysis (2014–2022 N=332). Data are presented for the most recent nine-year period for which cause of death data was available. [↑](#footnote-ref-56)
56. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-57)
57. External causes of injuries include intentional injuries (e.g., homicide and suicide), unintentional injuries (e.g., motor vehicle and non-transport related accidents), and injuries of undetermined intent. [↑](#footnote-ref-58)
58. Unintentional injuries include injuries such as motor vehicle-related and other transportation related deaths, falls, fires, and drownings that were not intended to occur. [↑](#footnote-ref-59)
59. Source: Massachusetts Department of Public Health, Office of Population Health. Note: 2022 and 2023 death data are preliminary. [↑](#footnote-ref-60)
60. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-61)
61. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-62)
62. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-63)
63. As of 1/1/2020, BIDLS calculates rates per 100,000 population using denominators estimated by the University of Massachusetts Donahue Institute using a modified Hamilton-Perry model. [↑](#footnote-ref-64)
64. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-65)
65. Among cities that reported at least 12 HIV infections during 2021–2023. [↑](#footnote-ref-66)
66. For more information, see: Joint MDPH and BPHC Clinical Advisory: Increase in newly diagnosed HIV infections among persons who inject drugs in Boston, March 15, 2021, available at: <https://www.mass.gov/doc/joint-mdph-and-bphc-clinical-advisory-hiv-transmission-through-injection-drug-use-in-boston-march-15-2021/download> [↑](#footnote-ref-67)
67. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-68)
68. Among cities that reported at least 50 PLWH as of 12/31/2023. Note: The rates of HIV prevalence for Provincetown, Shirley, and Ayer are high because of small population sizes (3,663, 7,431, and 8,479, respectively), as opposed to the number of cases (449, 63, and 67, respectively). [↑](#footnote-ref-69)
69. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-70)
70. For definitions of the care continuum stages, see [**Technical Note XX**](#technical_note_xx) [↑](#footnote-ref-71)
71. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-72)
72. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-73)
73. For definitions of the care continuum stages, see [**Technical Note XX**](#technical_note_xx) [↑](#footnote-ref-74)
74. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-75)
75. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-76)
76. For more information, see: <https://www.atsdr.cdc.gov/placeandhealth/svi/index.html> [↑](#footnote-ref-77)
77. Gant, Z., Dailey, A., Hu, X. et al. A Census Tract–Level Examination of Diagnosed HIV Infection and Social Vulnerability among Black/African American, Hispanic/Latinx, and White Adults, 2018: United States. J. Racial and Ethnic Health Disparities (2022). <https://doi.org/10.1007/s40615-022-01456-7> [↑](#footnote-ref-78)
78. Dasgupta S, Bowen VB, Leidner A, et al. Association Between Social Vulnerability and a County’s Risk for Becoming a COVID-19 Hotspot — United States, June 1–July 25, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1535–1541. DOI: <http://dx.doi.org/10.15585/mmwr.mm6942a3> [↑](#footnote-ref-79)
79. Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2023 data. [↑](#footnote-ref-80)